Advertisement
POSTER SESSION: New Therapies in Immuno-Oncology| Volume 138, SUPPLEMENT 2, S58, October 2020

TAS1553, a novel class of RNR inhibitor, has robust antitumor activity in murine syngeneic tumor models as a single agent and in combination with anti-PD-1 checkpoint inhibitor

DOI:https://doi.org/10.1016/S0959-8049(20)31232-6
TAS1553, a novel class of RNR inhibitor, has robust antitumor activity in murine syngeneic tumor models as a single agent and in combination with anti-PD-1 checkpoint inhibitor
Previous ArticleA phase I/II study of JX-594 oncolytic virus in combination with immune checkpoint inhibition in refractory colorectal cancer
Next ArticleA FliC armed oncolytic tanapoxvirus causes regression of colorectal cancer xenografts in immuno-competent models
      Background: Deoxyribonucleoside triphosphates (dNTPs) are the building blocks of DNA and are essential for cancer cell growth and survival. Ribonucleotide reductase (RNR) regulates a rate-limiting step in the supply of dNTP, which suggests RNR as a promising therapeutic target of cancer. TAS1553 is a novel class of RNR inhibitor that abrogates protein-protein interactions between RNR subunits; this compound has shown promising antitumor activity in preclinical models for both solid tumors and hematological malignancies.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      Article info

      Identification

      DOI: https://doi.org/10.1016/S0959-8049(20)31232-6

      Copyright

      © 2020 Elsevier B.V. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX